Proteomics

Dataset Information

0

DIPG harbour alterations targetable by MEK inhibitors, with acquired resistance mechanisms overcome by combinatorial inhibition


ABSTRACT: The survival of children with DIPG remains dismal, with new treatments desperately needed. In the era of precision medicine, targeted therapies represent an exciting treatment opportunity, yet resistance can rapidly emerge, playing an important role in treatment failure. In a prospective biopsy-stratified clinical trial, we combined detailed molecular profiling (methylation BeadArray, exome, RNAseq, phospho-proteomics) linked to drug screening in newly-established patient-derived models of DIPG in vitro and in vivo. We identified a high degree of in vitro sensitivity to the MEK inhibitor trametinib in samples which harboured genetic alterations targeting the MAPK pathway, including the non-canonical BRAFG469V mutation, and those affecting PIK3R1 and NF1. However, treatment of PDX models and the patient with trametinib at relapse failed to elicit a significant response. We generated trametinib-resistant clones in the BRAF_G469V model through continuous drug exposure, and identified acquired mutations in MEK1/2 (MEK1_K57N, MEK1_I141S and MEK2_I115N) with sustained pathway up-regulation. These cells showed the hallmarks of mesenchymal transition, and expression signatures overlapping with inherently trametinib-insensitive primary patient-derived cells that predicted a confirmed sensitivity to dasatinib. Combinations of trametinib with dasatinib and the downstream ERK inhibitor ulixertinib showed highly synergistic effects in vitro. These data highlight the MAPK pathway as a therapeutic target in DIPG, and show the importance of parallel resistance modelling and rational combinatorial treatments likely to be required for meaningful clinical translation.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: James Wright  

LAB HEAD: Jyoti Choudhary

PROVIDER: PXD019701 | Pride | 2021-07-20

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
EID1_TMT9plex_Full.msf Msf
EID1_TMT9plex_Full.pdResult Other
EID1and2_TMT9plex_FullProteome_MasterProteins.xlsx Xlsx
EID2_TMT9plex_Full.msf Msf
EID2_TMT9plex_Full.pdResult Other
Items per page:
1 - 5 of 99

Similar Datasets

2020-08-31 | E-MTAB-9282 | biostudies-arrayexpress
| EGAS00001004495 | EGA
2021-09-28 | GSE184786 | GEO
2021-07-30 | PXD022329 | Pride
2020-11-03 | GSE149682 | GEO
2023-06-30 | E-MTAB-13045 | biostudies-arrayexpress
2014-12-12 | E-GEOD-64102 | biostudies-arrayexpress
| EGAD00001008212 | EGA
| EGAD00001008211 | EGA
2013-06-30 | E-GEOD-44753 | biostudies-arrayexpress